Targeted Therapy & Precision Oncology
Part of Healthcare - Oncology
| Ticker | Company | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | $0.8t | $925.41 | -1.1% | 589.3K |
 RVMD | Revolution Medicines, Inc. Common Stock | $18.4b | $98.23 | -0.9% | 342.1K |
 INCY | Incyte Genomics Inc | $18.0b | $95.65 | -0.3% | 120.1K |
 JAZZ | Jazz Pharmaceuticals, Inc. | $11.3b | $186.56 | -0.2% | 132.9K |
 EXEL | Exelixis Inc | $10.9b | $44.00 | +0.3% | 329.4K |
 NUVL | Nuvalent, Inc. Class A Common Stock | $7.6b | $103.44 | -1.9% | 159.3K |
 HALO | Halozyme Therapeutics, Inc. | $7.4b | $64.03 | -0.7% | 237.7K |
 COGT | Cogent Biosciences, Inc. Common Stock | $5.7b | $35.33 | +0.3% | 214.6K |
 CELC | Celcuity Inc. Common Stock | $5.2b | $114.23 | +1.4% | 273.5K |
 ERAS | Erasca, Inc. Common Stock | $4.6b | $17.77 | -0.2% | 1.4M |
 CORT | Corcept Therapeutics Inc. | $4.1b | $42.42 | -0.2% | 204.7K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | $2.8b | $32.77 | +0.1% | 115.8K |
 TNGX | Tango Therapeutics, Inc. | $2.7b | $20.93 | -3.2% | 515.4K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.45 | +0.0% | 167.7K |
 IMNM | Immunome, Inc. | $2.2b | $22.20 | +1.6% | 145.0K |
 TYRA | Tyra Biosciences, Inc. Common Stock | $1.9b | $39.65 | +0.1% | 317.5K |
 ZYME | Zymeworks Inc. | $1.8b | $26.20 | +1.6% | 102.1K |
 RLAY | Relay Therapeutics, Inc. Common Stock | $1.7b | $13.03 | +3.9% | 1.1M |
 NRIX | Nurix Therapeutics, Inc. Common stock | $1.5b | $16.62 | +7.1% | 680.5K |
 DMRA | Damora Therapeutics, Inc. Common Stock | $1.5b | $25.22 | +0.5% | 48.1K |
 NUVB | Nuvation Bio Inc. | $1.4b | $4.61 | +4.4% | 959.7K |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | $1.4b | $9.38 | +5.5% | 773.9K |
 VIR | Vir Biotechnology, Inc. Common Stock | $1.4b | $9.09 | +0.3% | 250.6K |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $1.2b | $17.45 | +2.1% | 145.0K |
 BHVN | Biohaven Ltd. | $1.2b | $9.47 | -3.3% | 250.1K |
 NVCR | NovoCure Limited Ordinary Shares | $1.2b | $10.55 | -0.0% | 121.6K |
 OLMA | Olema Pharmaceuticals, Inc. Common Stock | $1.2b | $15.13 | +0.5% | 147.5K |
 AVBP | ArriVent BioPharma, Inc. Common Stock | $0.9b | $25.15 | +1.1% | 50.7K |
 GERN | Geron Corp | $0.9b | $1.75 | +5.7% | 6.0M |
 URGN | UroGen Pharma Ltd. Ordinary Shares | $0.8b | $19.19 | +2.0% | 128.3K |
 BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $0.7b | $9.04 | +1.4% | 101.7K |
 KURA | Kura Oncology, Inc. | $0.7b | $8.72 | +1.3% | 244.1K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.7b | $6.97 | -0.3% | 206.6K |
 ARVN | Arvinas, Inc | $0.7b | $11.28 | +3.9% | 424.7K |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $475.1m | $27.68 | +0.5% | 41.9K |
 ADCT | ADC Therapeutics SA | $462.4m | $3.73 | -1.2% | 223.8K |
 VSTM | Verastem, Inc. | $426.0m | $5.61 | -0.4% | 292.0K |
 STRO | Sutro Biopharma, Inc. | $399.3m | $24.13 | +1.5% | 40.2K |
 MNPR | Monopar Therapeutics Inc. Common Stock | $356.6m | $53.21 | -3.5% | 39.1K |
 IMRX | Immuneering Corporation Class A Common Stock | $315.5m | $5.52 | +1.2% | 282.7K |
 PBYI | PUMA BIOTECHNOLOGY INC | $311.9m | $6.81 | -1.3% | 102.7K |
 DCTH | Delcath Systems Inc | $308.9m | $9.75 | +1.2% | 53.9K |
 CCCC | C4 Therapeutics, Inc. | $229.3m | $2.94 | +4.1% | 493.7K |
 TLSI | TriSalus Life Sciences, Inc. Common Stock | $227.4m | $4.13 | -2.6% | 40.2K |
 NVCT | Nuvectis Pharma, Inc. Common Stock | $198.4m | $7.78 | +2.9% | 19.6K |
 PRLD | Prelude Therapeutics Incorporated | $193.4m | $3.85 | +11.4% | 93.3K |
 NTHI | NeOnc Technologies Holdings, Inc. Common Stock | $171.6m | $5.96 | +0.3% | 18.8K |
 WHWK | Whitehawk Therapeutics, Inc. Common Stock | $154.8m | $3.52 | +0.2% | 41.3K |
 CRBP | Corbus Pharmaceuticals Holdings, Inc. | $152.5m | $10.54 | +3.7% | 69.5K |
 ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | $151.8m | $2.62 | -0.2% | 172.9K |